Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
431. |
ECCT/23/07/04 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Dr. Janet Oyieko Site(s) in Kenya 1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 2. Gertrude\'s Children Hospital (Nairobi City county) 3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county) |
28-08-2023 |
View |
432. |
ECCT/23/08/02 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Nduba Videlis Site(s) in Kenya 1. Getrudes Children Hospital (Nairobi City county) 2. KEMRI/CRDR (Siaya county) 3. Kombewa CRC (Kisumu county) 4. Kondele Childrens Hospital (Kisumu county) |
18-10-2023 |
View |
433. |
ECCT/23/01/02 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Ogutu Bernhards Ragama Site(s) in Kenya 1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 2. Gertrude\'s Children Hospital (Nairobi City county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds, (Siaya county) 4. Kombewa CRC (Kisumu county) |
24-05-2023 |
View |
434. |
ECCT/23/01/03 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Githanga Githanga Nyokabi Site(s) in Kenya 1. Gertrude\'s Children Hospital (Nairobi City county) 2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county) 4. Kombewa CRC (Kisumu county) |
19-06-2023 |
View |
435. |
ECCT/21/11/05 | SOLIDARITY TRIAL PLUS An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Principal Investigator(s) 1. loice Ombajo Site(s) in Kenya 1. KENYATTA NATIONAL HOSPITAL SITE (Nairobi City county) 2. The Nairobi Hospital (Nairobi City county) |
13-01-2022 |
View |
436. |
ECCT/20/04/01 | Solidarity An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kilifi Kemri-Wellcome (Kilifi county) 2. Kenya National Hospital (Nairobi City county) 3. Coast PGH (Mombasa county) 4. The Nairobi Hospital (Nairobi City county) 5. Aga Khan University Hospital (Nairobi City county) 6. Moi Teahing and Referal Hospital (Uasin Gishu county) 7. Kenyatta University teaching research and referal hospital (Kiambu county) |
22-06-2020 |
View |
437. |
ECCT/14/09/01 | Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa An open extension to the phase III, multi-center study MALARIA-055 PRI (110021) to evaluate long-term efficacy, safety and immunogenicity of the RTS,S/AS01E candidate vaccine against malaria disease caused by Plasmodium falciparum in infants and children in Africa. Study number: MALARIA-076 (200599) |
Principal Investigator(s) 1. Walter Otieno Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project |
23-09-2015 |
View |
438. |
ECCT/19/11/06 | Optimize LNG EC An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375 |
Principal Investigator(s) 1. Lucy Chepkurui Koech Site(s) in Kenya KEMRI/WRP Kericho |
19-03-2020 |
View |
439. |
ECCT/21/05/06 | VAC52150EBL2010 ;Phase 2 An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen |
Principal Investigator(s) 1. Prof. Omu Anzala Omu Anzala Site(s) in Kenya KAVI-institute of Clinical Research |
11-08-2021 |
View |
440. |
ECCT/23/09/04 | GBT440-038Open-Label Extension An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children Hospital (Nairobi City county) 2. Kenya Medical Research Institute (KEMRI), Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 3. KEMRI CRDR SIAYA within Siaya County Referral Hospital Grounds (Siaya county) 4. Strathmore University Medical Center, Centre for Research in Therapeutic Sciences (Nairobi City county) |
12-12-2023 |
View |